Acrivon Therapeutics’ shares climb 14% on plans to present cancer-test data

Shares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovarian and endometrial cancers.
Article Attribution | Read More at Article Source
[mwai_chat context=”Let’s have a discussion about this article:nnShares of Acrivon Therapeutics advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with